Men diagnosed with azoospermia are told, in effect, that a laboratory looked at their semen sample and found no sperm. A newer approach argues that the problem may sometimes be the looking rather than the absence.
Systems combining high-speed microscopic imaging, machine learning, and microfluidics can scan millions of images from a single sample and flag cells that a human technician would not find in a realistic timeframe. A review of these methods from Columbia University Irving Medical Center appeared online in Current Opinion in Urology last month, summarizing the state of the field and concluding that further validation is required.
What follows matters for anyone weighing a fertility decision: the technical claim is credible, the published clinical evidence is thin, and those two things are frequently blurred in coverage. Couples considering paying for an add-on service should understand the difference between the options.
Azoospermia and the Search That Precedes Treatment
Azoospermia means no sperm is detected in the ejaculate on repeated analysis. Male factors account for roughly 40 percent of couples with infertility, and about 10 to 15 percent of men with infertility have azoospermia. The condition is classified as obstructive, where production is normal but the reproductive tract is blocked, or non-obstructive, where the testes produce little or no sperm.
Conventional laboratory practice involves spinning a sample in a centrifuge and having trained technicians manually inspect it under a microscope. The search is slow, physically fatiguing and inherently incomplete: a technician cannot examine every field of view in a sample within a workable timeframe.
"A semen sample can appear totally normal, but when you look under the microscope, you discover just a sea of cellular debris, with no sperm visible," said Zev Williams, director of the Columbia University Fertility Center, in a university announcement.
The surgical alternative is testicular sperm extraction, in which tissue is taken directly from the testis and searched. That procedure is frequently unsuccessful and carries risks including vascular problems, inflammation, and a temporary decrease in testosterone.
Imaging at Scale Versus a Technician's Eye
The Columbia system, called STAR for Sperm Tracking and Recovery, was developed using approaches borrowed from astrophysics, where algorithms identify rare objects across vast fields of imagery.
The instrument photographs an entire sample at high speed, generating more than 8 million images in under an hour. A machine learning model identifies candidate sperm within the debris, and a microfluidic chip isolates the portion of the sample containing the identified cell, according to Columbia. The isolation step avoids the centrifugation and chemical processing that can damage fragile cells.
Other groups are pursuing related approaches. The Columbia review notes that emerging technologies include augmented reality platforms that support embryologists during sperm searches and AI-integrated microfluidic systems capable of both detection and isolation, and that deep learning systems have improved the speed and sensitivity of sperm detection in both testicular tissue and ejaculate samples.
The common finding across these efforts is speed and coverage. Whether that translates into more babies is a separate question.
One Reported Pregnancy Is Not an Efficacy Result
Here is the part that deserves the most weight. Columbia reported the first clinical pregnancy using STAR in a research letter published in The Lancet, describing a single patient.
The details are specific, and the full author list and journal section are published alongside the case. The patient had struggled with infertility for nearly 20 years across multiple failed cycles, manual searches, and two surgical extractions. The system identified viable sperm that were used to create two embryos, and a transfer resulted in a pregnancy.
A research letter describing one case is a feasibility report, and The Lancet notes that research published in its Correspondence section is usually preliminary or exploratory. It demonstrates that the sequence can work. It does not establish how often it works, in which patients, or with what live birth rate. A single reported pregnancy cannot generate a success rate, and figures circulating in some coverage suggesting the method finds sperm in a large share of otherwise hopeless cases have not been substantiated by published peer-reviewed clinical trial data.
Columbia has said larger studies are underway to evaluate the method across broader patient populations. Those results have not been published.
Questions to Ask Before Paying for an Add-On
Fertility treatment is expensive and largely uninsured in much of the United States, which makes unproven add-on services a real financial risk for couples already under strain.
One further distinction deserves emphasis. Finding a sperm cell and producing a healthy live birth are separated by several steps, each with its own failure rate: fertilization, embryo development, transfer, and implantation. A method that improves the first step does not automatically improve the last one, and outcome data must be measured at the end of the chain rather than at the beginning.
Men diagnosed with azoospermia should first confirm the basics with a reproductive urologist: whether the diagnosis has been established on repeated analyses, whether the cause is obstructive or non-obstructive, and whether genetic and hormonal evaluations have been completed. Some causes are treatable, and the answer changes what options make sense.
For any AI-assisted sperm search offered by a clinic, reasonable questions include how many patients at that clinic have undergone the procedure, how many had sperm recovered, how many resulted in embryos, how many resulted in pregnancies, and how many resulted in live births. Clinics that cannot answer at the live birth level are describing a process rather than an outcome. Ask what the service costs beyond standard fees and whether it is billed separately if no sperm is found.
Nothing here suggests avoiding these technologies. The underlying imaging and detection work is real, and the alternative of a manual search has documented limitations. The reasonable posture is one of interest, with clear eyes, and a decision made with a reproductive urologist rather than based on coverage of a single case.
Insurance is the other practical constraint. Coverage for in vitro fertilization and associated services varies sharply by state and employer, and experimental or investigational add-ons are commonly excluded even where core treatment is covered. Couples should confirm in writing what a plan covers before scheduling, and ask the clinic whether the service is billed as investigational.
Larger clinical results are the next thing to watch.
Key Questions Answered
What is azoospermia? A condition in which no sperm is detected in the ejaculate on repeated analysis. It affects about 10 to 15 percent of men with infertility.
What does the AI method do? It photographs an entire sample at high speed, uses machine learning to identify rare sperm among cellular debris, and isolates them using a microfluidic chip.
How is that different from standard practice? Technicians manually search a centrifuged sample under a microscope, a slow process that cannot cover every field of view in a workable timeframe.
How many patients have been treated successfully? One clinical pregnancy has been reported in a peer-reviewed research letter. Larger studies are underway but have not been published.
Is a success rate established? No. A single case report demonstrates feasibility, not efficacy. No published trial data supports a specific success rate.
What should couples ask a clinic? How many patients have undergone the procedure there, and how many resulted in sperm recovery, embryos, pregnancies, and live births, plus what it costs?
Who should men consult? A reproductive urologist, who can confirm the diagnosis, determine whether the cause is obstructive or non-obstructive, and complete genetic and hormonal evaluation.
